Drug Trial Radar · NCT01499290
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
Last checked: Nov 20, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
493
Actual
Start
Mar 2012
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Forest Laboratories
- First posted
- Dec 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
Conditions
- Complicated Intra-Abdominal Infection
Interventions
CAZ-AVIDrug
Ceftazidime 2000 mg and 500 mg of avibactam
MetronidazoleDrug
500 mg of Metronidazole
MeropenemDrug
1 gram of Meropenem
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA).Time frame: TOC: 28 to 35 days after start of study drug
- Clinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set (Co-primary Outcome for Rest of World [ROW]).Time frame: TOC: 28 to 35 days after start of study drug
- Clinical Response at the TOC Visit in the Clinically Evaulable (CE) Analysis Set (Co-primary Outcome for Rest of World [ROW]).Time frame: TOC: 28 to 35 days after start of study drug
Locations
56 sites in 20 countries. Site status is shown where the registry gives one.
Research Site
Chula Vista, California
Research Site
San Diego, California
Research Site
St Louis, Missouri
Research Site
Somers Point, New Jersey
Research Site
Córdoba, Argentina
Research Site
Rosario, Argentina
Research Site
Rousse, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Zagreb, Croatia
Research Site
Děčín, Czechia
Research Site
Hradec Králové, Czechia
Research Site
Jihlava, Czechia
Research Site
Olomouc, Czechia
Research Site
Prague, Czechia
Research Site
Teplice, Czechia
Research Site
Budapest, Hungary
Research Site
Székesfehérvár, Hungary
Research Site
Bangalore, India
Research Site
Pune, India
Research Site
Trivandrum, India
Research Site
Vadodara, India
Research Site
Hadera, Israel
Research Site
Haifa, Israel
Research Site
Riga, Latvia
Research Site
Alor Star, Malaysia
Research Site
Durango, Mexico
Research Site
Guadalajara, Jalisco, Mexico
Research Site
Mexico City, Mexico
Research Site
's-Hertogenbosch, Netherlands
Research Site
Enschede, Netherlands
Research Site
Arequipa, Peru
Research Site
Cercardo de Lima, Peru
Research Site
Lima, Peru
Research Site
Trujillo, Peru
Research Site
Cluj-Napoca, Romania
Research Site
Iași, Romania
Research Site
Kemerovo, Russia
Research Site
Moscow, Russia
Research Site
Saratov, Russia
Research Site
Vsevolozhsk, Russia
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.